The headquarters of Seattle Genetics is located at Bothell Cascade Business Park. The building does not indicate anything to do with science but it has a green triangular sculpture at the lobby of the building which is made of Lego bricks and it is a symbol of a human antibody. The human antibody sculpture is a clear indication of what Seattle Genetics deal with ever since the inception of the firm. The medical organization was established in 1998 with a primary responsibility of manipulating, studying as well as manufacturing and packing antibody drugs. The antibody drugs developed by Seattle Genetics are used for cancer therapy. The antibodies distribute a toxic substance which goes to destroy cancer cells in the human body.
Seattle Genetics is the largest pharmaceutical organization in Washington, with a market value of about $10 billion and over 900 staff members. The pharmaceutical management team has big goals to make the group one of the largest pharmaceutical firms. To achieve their goal, the organization has invested heavily in research as well as marketing and recently they announced that they will be offering about 200 employment opportunities come next year. Seattle has a leading drug known as Adcetris which treats Hodgkin Lymphoma a cancer of the lymph system that can spread to other organs.
In 1998 Dr. Clay Siegall co-founded Seattle Genetics. Mr. Clay is not only the founder of one of the leading pharmaceutical firms which deal with the development of cancer drug therapy but he is also the President, the Chief Executive Officer and the Chairman of the Board of Directors. He is passionate about the medical and the pharmaceutical sector that is why he takes his time and effort to study on cancer treatment. During his leadership as the President and the Chief Executive Officer of the organization, Doctor Clay has been able to lead the company in the development of their flagship drug; Adcetris which was approved by the United States Food and Drug Administration in 2011.
Doctor Clay has a vast experience in the medical industry with him serving in several organizations among them; National Cancer Institute, National Institutes of Health, and Bristol-Myers Squibb Pharmaceutical Research Institute. A leader who has shown positive leadership a skill has been appointed to serve on the Board of Directors of organizations including; Alder Biopharmaceuticals. Dr. Siegall does not only practice medicine but he is also an author of more than 70 publications. He is a graduate of George Washington University with a Ph.D. in Genetics and Maryland University where he studied B.S in Zoology.